Dashenlin

2022 Informatization of China's Rehabilitation Industry

The rehabilitation industry caught the attention of the Chinese government again in 2021, and the industry entered a phase of accelerated development. The rehabilitation industry will first supplement medical resources and continue to explore a rehabilitation model that suits China's actual conditions. Under this context, EqualOcean Intelligence, together with Neusoft Group, released the 2022 Research Report On the Informatization of China's Rehabilitation Industry.

EqualOcean·LinkedIn|Event Preview: Global Business Collaboration and Diverse Team Building

On September 16, EqualOcean and LinkedIn will hold a offline panel on the theme of "Global Business Collaboration and Diverse Team Building", and enterprises dedicated to foreign trade and global business or those who have related plans are welcomed to register.

China to Implement Strict Regulatory Environment for Online Drug Sales

The State Administration for Market Regulation (SAMR) recently promulgated《Measures for the Supervision and Administration of Online Drug Sales》(Order of the State Administration for Market Regulation No. 58), which will take effect as of 1 December 2022.

15 Companies to Watch in August 2022- Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in August 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.

Analysis of In Vitro Diagnostics Industry in China

It has been almost three years since the coronavirus outbreak. In the post-Covid era, PCR tests and antigen reagents have become part of daily essentials. The increasing demand for PCR tests drives the development of IVD in China. What is IVD? How to explain its popularity in China over the past two or three years? You will find all the answers above in this article.